Prostatype Genomics AB enters into cooperation with leading actor in the prostate cancer area
– Agreement on marketing and R&D cooperation enhancing market position short- and long-termProstatype Genomics AB (“Prostatype Genomics”) has signed a cooperation agreement with Proteomedix AG (“Proteomedix”), a Zurich based science-driven company that has an approved product in the field of prostate cancer. The product is complementary to Prostatype®, the gene based prognostic tool developed and marketed by Prostatype Genomics. Used in different stages of the clinical process of prostate cancer, Prostatype® and the complementary product this will offer unique decision support for